Potent platelet inhibition is one of the most important medical interventions to prevent
ischemic complications during and after percutaneous coronary intervention (PCI).
Practice has evolved with the introduction of potent oral P2Y12 inhibitors that provide quick, effective platelet inhibition, and the need for routine
glycoprotein IIb/IIIa inhibitors (GPIs) has decreased. Additionally, a shorter duration
of GPI infusion has been shown to be safe with adequate oral antiplatelet loading,
but clinical outcome data are limited to eptifibatide. This single-center, retrospective
cohort study analyzed in-hospital outcomes for patients who received adjunctive GPI
therapy for PCI before and after an institution-wide switch to high-dose bolus tirofiban
with shortened infusion from short-duration eptifibatide. The primary end point was
a composite in-hospital outcome of major and minor bleeding and cardiovascular events
(death, myocardial infarction, coronary artery bypass grafting, ischemic stroke, and
target vessel revascularization). Secondary end points included bleeding and cardiovascular
event types. A total of 357 and 446 patients received eptifibatide and tirofiban,
respectively, from February 1, 2014 through September 30, 2017. Thirty five eptifibatide
and 46 tirofiban patients experienced an in-hospital composite event (9.8% vs 10.3%,
p = 0.81). There was no difference found between in-hospital bleeding (6.4% vs 5.4%,
p = 0.52) or cardiovascular events (5.6% vs 6.5%, p = 0.60) with the use of eptifibatide
or tirofiban, respectively. Multivariable analysis showed that patients with transradial
access or an indication of unstable angina were less likely to experience an in-hospital
composite event (OR 0.30 and 0.19, respectively, p <0.001 for both). In conclusion,
the use of high-dose bolus tirofiban with shortened infusion versus short-duration
eptifibatide was not associated with an increase of in-hospital bleeding or cardiovascular
events.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Reference
- 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes.J Am Coll Cardiol. 2014; 64: e139-e228
- 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction.J Am Coll Cardiol. 2013; 61: e78-e140
- Comparison of 1-year major adverse cardiac events in patients undergoing primary percutaneous coronary intervention receiving intracoronary bolus only versus intracoronary bolus plus infusion of glycoprotein IIb/IIIa inhibitors.Crit Pathw Cardiol. 2016; 15: 89-94
- Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The ICT-AMI study.Int J Cardiol. 2013; 165: 437-443
- Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.J Am Coll Cardiol. 2004; 44: 1187-1193
- High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.J Invasive Cardiol. 2008; 20: 53-58
- Prescribing Information.Merck & Co., Inc., Whitehouse Station, NJ2014
- Prescribing Information.Medicure Pharma, Inc., Somerset, NJ2016
- Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II.Lancet. 1997; 349: 1422-1428
- Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.N Engl J Med. 1998; 339: 436-443
- Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial.JAMA. 2001; 285: 2468-2473
- A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.N Engl J Med. 1998; 338: 1498-1505
- Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.N Engl J Med. 1998; 338: 1488-1497
- Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.Circulation. 1997; 96: 1445-1453
- The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE trial.J Am Coll Cardiol. 2004; 44: 14-19
- A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the Tirofiban Evaluation of Novel Dosing versus Abciximab with Clopidogrel and Inhibition of Thrombin (TENACITY) study trial.Catheter Cardiovasc Interv. 2011; 77: 1001-1009
- Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.JACC Cardiovasc Interv. 2012; 5: 268-277
- Effect of a shortened-duration eptifibatide infusion (75 mg) as adjunctive therapy for percutaneous coronary intervention on inhospital cardiovascular outcomes and bleeding.Am J Cardiol. 2015; 115: 707-710
- Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.J Am Coll Cardiol. 2013; 62: 2261-2273
- Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention.J Cardiovasc Med. 2011; 12: 29-36
- A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.Cardiovasc Ther. 2016; 34: 330-336
- Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.JAMA. 2008; 299: 1788-1799
- Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial.Lancet. 2008; 372: 537-546
- Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngioLastiche dell'Emilia-Romagna) multicenter registry.JACC Cardiovasc Interv. 2012; 5: 23-35
- Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry.Circ Cardiovasc Interv. 2009; 2: 222-229
- Ticagrelor and eptifibatide bolus versus ticagrelor and eptifibatide bolus with 2-hour infusion in high-risk acute coronary syndromes patients undergoing early percutaneous coronary intervention.J Am Heart Assoc. 2017; 6e005562
Article info
Publication history
Published online: September 26, 2018
Accepted:
September 18,
2018
Received in revised form:
September 17,
2018
Received:
August 2,
2018
Footnotes
Funding: This research was funded in part by a grant from the Mayo Clinic Department of Pharmacy
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
